Covid-19 vaccine researchers hope to be able to restart trials soon.
AstraZeneca halted its trials last week after a severe reaction that may not have been induced by the vaccine.
CEO …
This item is available in full to subscribers.
Please log in to continueNeed an account?
|
Covid-19 vaccine researchers hope to be able to restart trials soon.
AstraZeneca halted its trials last week after a severe reaction that may not have been induced by the vaccine.
CEO Pascal Soriot said in a private call with investors that a woman in the UK developed neurological issues.
Her condition is improving, and she was expected to return home this week.
Reports earlier said she may have developed a condition called transverse myelitis.
Researchers are looking at whether it could have been caused by the experimental vaccine.
The AstraZeneca/Oxford University vaccine partnership is one of the frontrunners in the vaccine race.
Oxford was among the 1st few companies to publish promising results for immunity.
The vaccine is 1 of 3 advanced experimental drugs that have reached Phase 3 trials in America and Europe
AstraZeneca has deals with the US and other countries for hundreds of millions of doses if the vaccine is safe and effective.
Other items that may interest you
Comments
No comments on this item Please log in to comment by clicking here